Humankind Investments LLC Boosts Position in Johnson & Johnson $JNJ

Humankind Investments LLC increased its holdings in Johnson & Johnson (NYSE:JNJ) by 214.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,822 shares of the company’s stock after acquiring an additional 14,874 shares during the quarter. Johnson & Johnson comprises approximately 0.8% of Humankind Investments LLC’s portfolio, making the stock its 19th biggest position. Humankind Investments LLC’s holdings in Johnson & Johnson were worth $3,333,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in JNJ. Clark Asset Management LLC lifted its holdings in shares of Johnson & Johnson by 51.6% during the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after purchasing an additional 3,025 shares during the last quarter. Apexium Financial LP increased its position in Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after buying an additional 2,310 shares in the last quarter. Avanza Fonder AB raised its stake in Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after buying an additional 6,566 shares during the last quarter. Winnow Wealth LLC bought a new stake in Johnson & Johnson in the second quarter worth $295,000. Finally, 111 Capital increased its holdings in shares of Johnson & Johnson by 94.0% during the second quarter. 111 Capital now owns 12,474 shares of the company’s stock valued at $1,905,000 after acquiring an additional 6,045 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Scotiabank initiated coverage on shares of Johnson & Johnson in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 target price on the stock. Raymond James Financial raised their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. UBS Group upped their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. Finally, Guggenheim lifted their target price on Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $206.65.

Johnson & Johnson Stock Up 0.8%

Shares of Johnson & Johnson stock opened at $211.65 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $212.27. The company has a market cap of $509.93 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 2.34 and a beta of 0.36. The company’s 50 day moving average is $196.09 and its 200 day moving average is $177.08.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.